Susceptibilities of Legionella spp. to newer antimicrobials in vitro.
The in vitro activities of 13 antimicrobial agents against 30 strains of Legionella spp. were determined. Rifapentine, rifampin, and clarithromycin were the most potent agents (MICs at which 90% of isolates are inhibited [MIC90s], < or = 0.008 microgram/ml). The ketolide HMR 3647 and the fluoroquinolones levofloxacin and BAY 12-8039 (MIC90s, 0.03 to 0.06 microgram/ml) were more active than erythromycin A or roxithromycin. The MIC90s of dalfopristin-quinupristin and linezolid were 0.5 and 8 micrograms/ml, respectively. Based on class characteristics and in vitro activities, several of these agents may have potential roles in the treatment of Legionella infections.
Schülin
T
T
Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA.
Wennersten
C B
CB
Ferraro
M J
MJ
Moellering
R C
RC
Eliopoulos
G M
GM
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D001372:Aza Compounds; D024841:Fluoroquinolones; D006801:Humans; D048628:Ketolides; D007875:Legionella / Q000187:drug effects*; D018942:Macrolides; D008826:Microbial Sensitivity Tests; D000077266:Moxifloxacin; D011804:Quinolines; D015363:Quinolones / Q000494:pharmacology; D012293:Rifampin / Q000031:analogs & derivatives / Q000494:pharmacology
D000900:Anti-Bacterial Agents; D001372:Aza Compounds; D024841:Fluoroquinolones; D048628:Ketolides; D018942:Macrolides; D011804:Quinolines; D015363:Quinolones; C106791:telithromycin; D000077266:Moxifloxacin; D012293:Rifampin; C018421:rifapentine